New hope for lung cancer patients: drug combo targets remaining cancer cells after chemoradiation

NCT ID NCT07091305

Recruiting now Disease control Sponsor: Shanghai Chest Hospital Source: ClinicalTrials.gov ↗

First seen Jun 12, 2026 · Last updated Jun 18, 2026 · Updated 2 times

Summary

This study tests whether adding the drug QL1706 (which boosts the immune system) to chemotherapy before standard chemoradiation, followed by more immunotherapy, can help people with limited-stage small cell lung cancer live longer without the cancer growing. About 28 adults aged 18-75 with measurable tumors and good organ function are eligible. The goal is to see if this approach improves outcomes compared to current treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHEMORADIOTHERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Shanghai Chest Hospital
RECRUITING

Shanghai, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHEMORADIOTHERAPY CONSOLIDATION IMMUNOTHERAPY INDUCTION THERAPY LIMITED-STAGE SMALL CELL LUNG CANCER (LS-SCLC)